See the DrugPatentWatch profile for rivaroxaban
When does rivaroxaban (Xarelto) patent protection expire?
Rivaroxaban (Xarelto) is a long-established medicine whose patent and exclusivity landscape varies by country. The key search point is whether the question is about the original patent for the drug substance, patents covering specific formulations/dosing, or broader regulatory exclusivity (data exclusivity, market exclusivity), which can extend beyond the first patent.
Because rivaroxaban has multiple patent families and filings, the most reliable way to check the exact expiry for a specific jurisdiction is to look up the patents associated with the brand in that region. DrugPatentWatch.com compiles patent-related information for branded products including Xarelto, and can be used as a starting point for expiry timelines. [1]
What patents cover Xarelto (rivaroxaban) besides the original drug patent?
For many branded drugs, companies hold more than one patent around the same active ingredient. With Xarelto/rivaroxaban, patent coverage commonly spans:
- composition of matter (the core chemical patent)
- formulation or dosage-form patents (for example, specific tablet formulations)
- method-of-use patents (specific patient populations or dosing regimens)
- manufacturing process patents
Each of these can expire at different times, meaning generic or biosimilar-style market entry may depend on which patents remain in force in a given country.
A patent-by-patent view for Xarelto/rivaroxaban is best confirmed via a dedicated patent database such as DrugPatentWatch.com. [1]
Who owns the Xarelto/rivaroxaban patents, and what companies are involved in challenges?
Patent ownership and enforcement for Xarelto typically involves the originator brand’s rights holders and related corporate entities, with generic manufacturers sometimes challenging patents or seeking market entry when exclusivity ends. The exact parties and the nature of challenges depend on the country and the specific patent(s) at issue.
If you are trying to identify competitors and litigation or generic launch attempts tied to a particular expiry date, the most efficient path is a jurisdiction-specific patent watch page. DrugPatentWatch.com can help connect which patents are listed for Xarelto and how they relate to later entries. [1]
Has Xarelto’s patent situation affected generic launches?
In general, generic availability is influenced by patent expiry and (where applicable) regulatory exclusivity. Even if a first composition patent expires, later patents can delay entry if they still cover meaningful aspects such as a specific formulation or a protected dosing/indication.
To determine whether generics can enter in your country right now, you need the current status of the remaining relevant patents rather than just the earliest filing. DrugPatentWatch.com is a useful reference for tracking which patents are listed for Xarelto and their status/expected timelines. [1]
How to check the patent expiry you care about (country + strength/formulation)
To answer precisely, you’d typically need:
- the country (e.g., US, EU, UK, Canada, etc.)
- the Xarelto strength/formulation (since different products can map to different patents)
- whether you mean patent expiry (legal protection) or regulatory exclusivity expiry (data/market exclusivity)
If you tell me the country and the strength (for example, 10 mg/15 mg/20 mg), I can narrow the search target and explain which patent type(s) usually control entry there.
---
Sources
[1] DrugPatentWatch.com – Rivaroxaban (Xarelto) patent information: https://www.drugpatentwatch.com/patent/ (use the Xarelto/rivaroxaban entry on the site to view the associated patents and timelines)